Perfil da empresa · Healthcare

ADMA Biologics Inc

ADMA · EUA
País / Região
USA
Data do IPO
17 de outubro de 2013
Funcionários
640
Buffett Score
29/100
Ruim
Valor de mercadoUS$ 2,18 bi
Receita (TTM)US$ 512,28 mi
EBITDAUS$ 224,19 mi
Margem líquida32,98%
ROE41,9%
P/L (TTM)13,89
P/L projetado9,78
PEG0
LPAUS$ 0,70
Faixa de 52 semanasUS$ 7,21 – US$ 20,46
Preço-alvo dos analistasUS$ 17,00
Recomendação dos analistas4.3 / 5

Dados da EODHD, apresentados na moeda de reporte; apenas para referência, não constitui recomendação de investimento.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

História

Em breveEsta seção está sendo preenchida — volte em breve.

Posição no setor

Em breveEsta seção está sendo preenchida — volte em breve.

Ainda não há análises sobre este ativo no seu idioma.